A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Conditions
Higher-risk Myelodysplastic Syndromes
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda), Bethesda, Maryland, United States
Maryland Oncology-Columbia, Columbia, Maryland, United States
Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
Montefiore Einstein Comprehensive Cancer Center, The Bronx, New York, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Gabrail Cancer Center, Canton, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Oncology Associates of Oregon, Eugene, Oregon, United States
MUSC Hollings Cancer Center, Charleston, South Carolina, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Institute of hematolongy&blood diseases hospital, chinese academy of medical sciences&peking union medical college, Tianjin, China
Contact: Study coordinator (Zhijian Xiao)